Cantor Fitzgerald Reiterates Alnylam Pharmaceuticals (ALNY) at Neutral on Good Execution
Tweet Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating and $450.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
